Literature DB >> 14526205

Hospitalization rates differ by hepatitis C satus in an urban HIV cohort.

Kelly A Gebo1, Marie Diener-West, Richard D Moore.   

Abstract

OBJECTIVE: To determine whether hepatitis C virus (HCV) infection status affected hospitalization rates, intensive care utilization rates, and discharge diagnoses between 1995 and 2000 in patients with HIV.
METHODS: We conducted a prospective cohort study of 3730 HIV patients who were longitudinally followed between 1995 and 2000. All hospitalizations of these patients were classified as an opportunistic illness (OI) using the 1993 indicator diagnoses in the case definition of AIDS, complication of injection drug use (IDU) (abscess, cellulitis, osteomyelitis, bacteremia, endocarditis, and poisoning by analgesics), liver-related complication (acute and subacute necrosis of the liver, chronic liver disease and cirrhosis, liver abscess, hepatic coma, portal hypertension, hepatorenal syndrome, hepatocellular carcinoma, and gastrointestinal bleed), or other. Negative binomial regression was used to assess for risk factors for hospitalization. MAIN OUTCOME MEASURES: Inpatient hospitalization and intensive care utilization rates and discharge diagnoses.
RESULTS: Nearly half (42.8%) of our cohort was infected with HCV. Between 1995 and 2000, hospitalization rates for HCV-negative patients decreased from 61.9 to 33.9 per 100 patient-years (PY) of follow-up (P = 0.007). Hospitalization rates decreased between 1995 and 1997 for HCV-positive patients from 55.4 to 43.5 per 100 PY but increased between 1997 and 2000 from 43.5 to 62.9 per 100 PY (P = 0.001). When stratified by diagnostic category, IDU-related complications increased from 13.6 to 18.4 admissions per 100 PY and liver-related complications increased from 5.4 to 26.7 admissions per 100 PY between 1995 and 2000 in HCV-positive patients (P < 0.001); however, OIs remained relatively unchanged from 1995 to 2000, with 14.6 to 13.0 hospitalizations per 100 PY. In multivariate analysis, HCV infection (incidence rate ratio [IRR] = 1.75, 95% confidence interval [CI]: 1.47, 2.07), female gender (IRR = 1.56, 95% CI: 1.32, 1.85), age <37 years (IRR = 1.19, 95% CI: 1.01, 1.41), African American ethnicity (IRR = 1.30, 95% CI: 1.05, 1.61), and CD4 cell count <50 cells mm3 (IRR = 2.20, 95% CI: 1.72, 2.83) were predictive of hospitalization.
CONCLUSIONS: Our data indicate that hospitalization rates decreased significantly between 1995 and 2000 for HCV-negative patients but increased significantly for HCV-positive patients. Hospitalization rates for IDU- and liver-related complications increased during this time interval in coinfected patients. In the era of highly active antiretroviral therapy, HIV/HCV-coinfected patients are more likely to suffer from higher hospitalization rates, which will require more health care resources.

Entities:  

Mesh:

Year:  2003        PMID: 14526205     DOI: 10.1097/00126334-200310010-00006

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  34 in total

1.  Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE).

Authors:  Farzana Kapadia; Mary H Latka; Holly Hagan; Elizabeth T Golub; Jennifer V Campbell; Micaela H Coady; Richard S Garfein; David L Thomas; Sebastian Bonner; Thelma Thiel; Steffanie A Strathdee
Journal:  J Urban Health       Date:  2007-01       Impact factor: 3.671

2.  Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection.

Authors:  Camilla S Graham; Annalee Wells; Tun Liu; Kenneth E Sherman; Marion Peters; Raymond T Chung; Atul K Bhan; Janet Andersen; Margaret James Koziel
Journal:  AIDS       Date:  2006-02-14       Impact factor: 4.177

3.  Risk factors for liver fibrosis among human immunodeficiency virus monoinfected patients using the FIB4 index in Morocco.

Authors:  Mohamed Tahiri; Mustapha Sodqi; Fatima Ez Zahra Lahdami; Latifa Marih; Hassan Lamdini; Wafaa Hliwa; Ahd Oulad Lahcen; Wafaa Badre; Fouad Haddad; Abdelfetah Chakib; Ahmed Bellabah; Rhimou Alaoui; Kamal Marhoum El Filali
Journal:  World J Hepatol       Date:  2013-10-27

4.  Psychosocial correlates of HIV-monoinfection and HIV/HCV-coinfection among men who have sex with men.

Authors:  David W Pantalone; Danielle M Hessler; Sarah M Bankoff; Brijen J Shah
Journal:  J Behav Med       Date:  2011-09-23

5.  Hospitals as a 'risk environment': an ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs.

Authors:  Ryan McNeil; Will Small; Evan Wood; Thomas Kerr
Journal:  Soc Sci Med       Date:  2014-01-19       Impact factor: 4.634

6.  Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008.

Authors:  Stephen A Berry; John A Fleishman; Richard D Moore; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

Review 7.  Hepatitis C virus infection in HIV-infected patients.

Authors:  Mark S Sulkowski
Journal:  Curr HIV/AIDS Rep       Date:  2004-09       Impact factor: 5.071

8.  Hospitalization Rates and Outcomes Among Persons Living With Human Immunodeficiency Virus in the Southeastern United States, 1996-2016.

Authors:  Thibaut Davy-Mendez; Sonia Napravnik; David A Wohl; Amy L Durr; Oksana Zakharova; Claire E Farel; Joseph J Eron
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

9.  Hospitalization risk following initiation of highly active antiretroviral therapy.

Authors:  S A Berry; Y C Manabe; R D Moore; K A Gebo
Journal:  HIV Med       Date:  2009-12-08       Impact factor: 3.180

10.  Inpatient health services utilization among HIV-infected adult patients in care 2002-2007.

Authors:  Baligh R Yehia; John A Fleishman; Perrin L Hicks; Michelande Ridore; Richard D Moore; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2010-03       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.